Envista Holdings Co. (NYSE:NVST) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers increased its stake in Envista Holdings Co. (NYSE:NVST) by 1.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 474,259 shares of the company’s stock after acquiring an additional 6,421 shares during the period. Rhumbline Advisers owned approximately 0.28% of Envista worth $9,148,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Creative Planning lifted its stake in Envista by 30.2% in the third quarter. Creative Planning now owns 31,575 shares of the company’s stock worth $624,000 after acquiring an additional 7,329 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Envista by 69.7% in the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after purchasing an additional 804 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Envista by 50.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after purchasing an additional 728 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Envista during the third quarter worth $31,000. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in Envista by 11.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 15,314 shares of the company’s stock valued at $303,000 after buying an additional 1,538 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have issued reports on NVST. Robert W. Baird lifted their price target on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, October 31st. Piper Sandler boosted their target price on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Leerink Partnrs raised Envista from a “strong sell” rating to a “hold” rating in a report on Thursday, October 31st. Morgan Stanley raised their price objective on shares of Envista from $19.00 to $20.00 and gave the stock an “equal weight” rating in a report on Thursday, February 6th. Finally, Mizuho initiated coverage on shares of Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 target price for the company. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Envista has a consensus rating of “Hold” and an average price target of $20.21.

Envista Stock Up 2.4 %

Shares of NYSE:NVST opened at $21.36 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The stock has a market cap of $3.68 billion, a P/E ratio of -3.29, a P/E/G ratio of 1.27 and a beta of 1.34. Envista Holdings Co. has a 1-year low of $15.15 and a 1-year high of $23.00. The firm has a fifty day moving average price of $20.15 and a 200 day moving average price of $19.59.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Sell-side analysts predict that Envista Holdings Co. will post 1 EPS for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.